The Trump administration is considering a regulatory approach to lower U.S. drug prices, potentially aligning them with those of other wealthy nations, sparking industry opposition and possible legal challenges. This move follows previous attempts to address price disparities and demands for voluntary price reductions, with the administration also exploring tariffs and other measures to pressure drugmakers.